Adaptive Biotechnologies Files Definitive Proxy for Annual Meeting, Details Executive Compensation and Equity Plan Expansion

summarizeSummary

Adaptive Biotechnologies filed its definitive proxy statement for the 2026 Annual Meeting, detailing executive compensation, board elections, and a significant increase in its equity incentive plan reserve for future grants.

check_boxKey Events

• Annual Shareholder Meeting Scheduled

  The company will hold its Annual Meeting on June 5, 2026, with a record date of April 7, 2026, to vote on key corporate matters.

• Executive Compensation Details and Changes

  The filing provides comprehensive executive compensation data for 2025, including a CEO pay ratio of 47 to 1. For 2026, the compensation philosophy shifts to a 50% RSU and 50% PSU mix for executive officers, adding an MRD revenue CAGR metric to PSUs, reflecting a focus on performance alignment.

• Significant Equity Plan Expansion

  The 2019 Equity Incentive Plan reserve increased by 7,688,970 shares effective January 1, 2026, providing substantial capacity for future equity grants and representing a notable potential for dilution.

• Director Elections and Auditor Ratification

  Shareholders will vote on the re-election of two Class I directors, Robert Hershberg and Katey Owen, and the ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026.

auto_awesomeAnalysis

This definitive proxy statement outlines the agenda for Adaptive Biotechnologies' upcoming annual shareholder meeting on June 5, 2026. Key proposals include the election of two Class I directors, an advisory vote on executive compensation, and the ratification of Ernst & Young LLP as the independent auditor. The filing details the company's executive compensation philosophy, which is evolving to include a higher proportion of performance-based equity awards and new metrics like MRD revenue CAGR, demonstrating responsiveness to shareholder feedback. Notably, the company's 2019 Equity Incentive Plan reserve increased by 7,688,970 shares effective January 1, 2026, providing substantial capacity for future equity issuance and potential dilution. The filing also discloses related party transactions, including executive investments in a corporate subsidiary, Digital Biotechnologies, Inc., which are stated to be on arm's-length terms.